// App-Quantinova.ai

2085 : GATA3 Gene - a Potential New Biomarker Associated with Adverse Outcomes in ALK1-Negative Anaplastic Large Cell Lymphoma: Preliminary Results from a Retrospective Cohort of 80 South American Cases of Nodal Peripheral T Lymphoma

Researchers

Presenter

  • Luis Alberto de Padua Covas Lage

Principal Investigators

  • Claudio Vinicius Brito

  • Debora Levy

  • Hebert Fabricio Culler

  • Samuel Campanelli Freitas Couto

  • Lucas BO Alves

  • Maria C Zerbini

  • Vanderson Rocha

  • Juliana Pereira

Medical Centers

  • Medical Research Laboratory on Molecular Hematology (LIM-31), University of São Paulo, Sao Paulo, Sp, Brazil

  • Departament of Hematology, Hemotherapy and Cell Therapy, Hospital Das Clinicas Da Universidade De Sao Paulo, São Caetano do Sul, SP, Brazil

  • Department of Hematology, Hemotherapy and Cell Therapy, Universidade de São Paulo (USP), Sao Paulo, Brazil

  • Medical Research Laboratory on Immunology and Histocompatibility (LIM-19), Universidade de São Paulo, São Paulo, Brazil

  • Department of Hematology- Hospital das Clínicas da Faculdade de Medicina da USP- HCFMUSP, Universidade de São Paulo (USP), Sao Paulo, Brazil

  • Medical Laboratory Investigation 31 - LIM31, Universidade de São Paulo (USP), Sao Paulo, Brazil

  • Serviço de Hematologia, Hemoterapia e Terapia Celular - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo/Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil

  • University of Sao Paulo, Sao Paulo, Brazil

  • Pathology department, Universidade de São Paulo, Sao Paulo, Brazil

  • ICESP Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

  • Bone Marrow Transplant Unit, Hospital Sirio Libanes, São Paulo, Brazil

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Division of Hematology, Hospital das Clínicas da Faculdade de Medicina (HCFMUSP), University of São Paulo Medical School, University of São Paulo, São Paulo, Brazil

  • Universidade de Sao Paulo (USP), Sao Paulo, Brazil

  • Instituto do Cancer de São Paulo (ICESP), University of São Paulo Medical School, University of São Paulo, São Paulo, Brazil

  • Centro de Oncologia, Hospital Sírio Libanês, São Paulo, Brazil

  • Division of Hematology, Transfusion Medicine and Cell Therapy, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

  • Instituto, Sao Paulo, SP, BRA

  • PRQFSA, Sao Paulo, SP, BRA

  • Division of Hematology, Hospital das Clínicas da Faculdade de Medicina (HCFMUSP), Sao Paulo, Universidade de Sao Paulo, Sao Paulo, AC, BRA

  • MEDICINE SCHOOL OF SAO PAULO UNIVERSITY, SAO PAULO, BRA

  • Division of Rheumatology, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, sao paulo, Sao Paulo, Brazil

  • Instituto do Cancer de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

Locations

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Solid malignancies

Biomarkers

  • GATA Binding Protein 3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved